LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19.

    Hussein, Heba / Brown, Ronald

    Oral surgery, oral medicine, oral pathology and oral radiology

    2020  Volume 131, Issue 1, Page(s) e9–e13

    Abstract: ... for the treatment of oral lesions, such as Sjogren syndrome (SS), chronic ulcerative stomatitis (CUS), and ... oral lichen planus (OLP). Because HCQ may be appropriately used for the off-label treatment of SS, CUS, and OLP ... for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed ...

    Abstract The Food and Drug Administration has recently approved the off-label use of hydroxychloroquine (HCQ) for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed to demonstrate HCQ efficacy but also documented a serious side effect of COVID-19 therapy with HCQ: QT prolongation and secondary arrhythmia. HCQ has been used as an off-label drug and deemed safe and effective for the treatment of oral lesions, such as Sjogren syndrome (SS), chronic ulcerative stomatitis (CUS), and oral lichen planus (OLP). Because HCQ may be appropriately used for the off-label treatment of SS, CUS, and OLP, relevant safety concerns regarding HCQ therapy with regard to dosage, drug-to-drug interactions, and QT prolongation and secondary arrhythmia are discussed here. Because of the possibility of decreased pharmacy supplies of HCQ, replacement drugs with respect to patients with SS, CUS, and OLP being successfully treated with HCQ are also discussed.
    Keywords covid19
    Language English
    Publishing date 2020-06-20
    Publishing country United States
    Document type Journal Article ; Review ; Comment
    ZDB-ID 2650843-6
    ISSN 2212-4411 ; 2212-4403
    ISSN (online) 2212-4411
    ISSN 2212-4403
    DOI 10.1016/j.oooo.2020.06.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19

    Hussein, Heba / Brown, Ronald

    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology ; ISSN 2212-4403

    2020  

    Keywords Pathology and Forensic Medicine ; Surgery ; Oral Surgery ; Dentistry (miscellaneous) ; Radiology Nuclear Medicine and imaging ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    DOI 10.1016/j.oooo.2020.06.011
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19

    Hussein, Heba / Brown, Ronald

    Oral surgery, oral medicine, oral pathology and oral radiology

    Abstract: ... for the treatment of oral lesions, such as Sjogren syndrome (SS), chronic ulcerative stomatitis (CUS), and ... oral lichen planus (OLP). Because HCQ may be appropriately used for the off-label treatment of SS, CUS, and OLP ... for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed ...

    Abstract The Food and Drug Administration has recently approved the off-label use of hydroxychloroquine (HCQ) for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed to demonstrate HCQ efficacy but also documented a serious side effect of COVID-19 therapy with HCQ: QT prolongation and secondary arrhythmia. HCQ has been used as an off-label drug and deemed safe and effective for the treatment of oral lesions, such as Sjogren syndrome (SS), chronic ulcerative stomatitis (CUS), and oral lichen planus (OLP). Because HCQ may be appropriately used for the off-label treatment of SS, CUS, and OLP, relevant safety concerns regarding HCQ therapy with regard to dosage, drug-to-drug interactions, and QT prolongation and secondary arrhythmia are discussed here. Because of the possibility of decreased pharmacy supplies of HCQ, replacement drugs with respect to patients with SS, CUS, and OLP being successfully treated with HCQ are also discussed.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #608748
    Database COVID19

    Kategorien

To top